Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 11.03.2021.

#biotechnology
#CRISPR
#lifesciences
#pharmaceuticals
#SARSCoV2
#biospace
#influenza
#NBTintheNews
#geneediting
#AI

Companies And Industries

@BiotechWorld shared
On Mar 9, 2021
Ex-Intercept CMO Campagna lands at immune regulation biotech Q32 https://t.co/HgPxRLlxbA https://t.co/xpF7pdL80b
Open
Ex-Intercept CMO Campagna lands at immune regulation biotech Q32

Ex-Intercept CMO Campagna lands at immune regulation biotech Q32

Jason Campagna has taken up the chief medical officer position (CMO) at Q32 Bio. Campagna arrives at Q32 after a stint at Intercept Pharmaceuticals that saw him rise to the CMO role at the ...

@BiotechWorld shared
On Mar 8, 2021
Merck has better luck with 2nd COVID-19 drug attempt as it sees a positive in early molnupiravir data https://t.co/qVMPxG4eVG https://t.co/UiqzBuABIU
Open
Merck has better luck with 2nd COVID-19 drug attempt as it sees a positive in early molnupiravir data

Merck has better luck with 2nd COVID-19 drug attempt as it sees a positive in early molnupiravir data

Merck has had a torrid time with COVID-19 vaccines and a major setback with its OncoImmune-partnered pandemic med, but now, finally, it’s seeing some good news on that R&D front.

@Biotechnology shared
On Mar 9, 2021
Report: 2021 Could Represent a Major Shift in Central Nervous System Therapeutics https://t.co/zdT9QEH6wt https://t.co/Dw4yQzeoML
Open
Report: 2021 Could Represent a Major Shift in Central Nervous System Therapeutics

Report: 2021 Could Represent a Major Shift in Central Nervous System Therapeutics

One of the key drivers of a shift in CNS drugs hinges on the success or failure of Biogen’s aducanumab for Alzheimer’s disease.

@NatureBiotech shared
On Mar 10, 2021
@LabRoots Inhaled #CRISPR treatment targets #influenza and #SARSCoV2 infections #NBTintheNews via @GENbio https://t.co/BicD5nTRAK
Open
Inhaled CRISPR Treatment Targets Influenza and SARS-CoV-2 Infections

Inhaled CRISPR Treatment Targets Influenza and SARS-CoV-2 Infections

The treatment uses a type of CRISPR to target viral RNA and appears to stop replication of both viruses in the lungs.

@BiotechWorld shared
On Mar 8, 2021
CytoDyn digs deep for signs of efficacy in COVID-19 trial flop https://t.co/hpFiD0zoj2 https://t.co/RE0JidVjGO
Open
CytoDyn digs deep for signs of efficacy in COVID-19 trial flop

CytoDyn digs deep for signs of efficacy in COVID-19 trial flop

A phase 3 clinical trial of CytoDyn’s leronlimab in COVID-19 patients has missed its primary and all major secondary endpoints. However, CytoDyn zeroed in on a subgroup of patients and ...

@biospace shared
On Mar 9, 2021
2021 Biopharma Update on the Novel Coronavirus: March 9 #biospace #lifesciences #biotechnology #pharmaceuticals https://t.co/6Hs9ChWQir
Open
2021 Biopharma Update on the Novel Coronavirus: March 9

2021 Biopharma Update on the Novel Coronavirus: March 9

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.

@FiercePharma shared
On Mar 9, 2021
GlaxoSmithKline CEO Walmsley's pay falls to $9.7M as pandemic drags on profits https://t.co/AGqyTpXyn9
Open
GlaxoSmithKline CEO Walmsley's pay falls to $9.7M as pandemic drags on profits

GlaxoSmithKline CEO Walmsley's pay falls to $9.7M as pandemic drags on profits

GlaxoSmithKline managed to notch some wins during the pandemic-challenged year of 2020, but COVID-19 took its toll—not only on the British pharma's finances, but on CEO Emma Walmsley’s pay, ...

@LillyPad shared
On Mar 8, 2021
New: Lilly and Biolojic Design announce a research collaboration to discover and develop antibody therapies for the treatment of #diabetes. Learn more: https://t.co/drMpyrkAFK #AI #biotechnology https://t.co/rYwE59dlwU
Open
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.